In this study, a patient received two local injections of TELOXOME, a novel stem cell-derived agent developed by ContiNew Medical. The injections were administered to the patient's left knee, with the injections separated by 3 weeks. The patient underwent magnetic resonance imaging (MRI) of the knee before and at 6 months after the TELOXOME injections. The MRI scans revealed a significant improvement in chondromalacia following the two TELOXOME injections. This finding indicates that TELOXOME may be an effective treatment option for chondromalacia, especially in cases where traditional treatments have failed.